Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal ethamsylate for hereditary hemorrhagic telangiectasia
2016-003982-24Phase 2Completed
- Sponsor
- Asociación HHT España
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etamsylate in hereditary hemorrhagic telangiectasia (HHT), sponsored by Asociación HHT España. Primary endpoint: Number of epistaxis per week. Started Dec 2016; status: completed.
02
Drugs
etamsylate
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2016-003982-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003982-24.